ERLOTERO TABS 100 MG 30'S

About

ERLOTERO TABS 100 MG 30'S contains Erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It works by blocking the activity of the EGFR, a protein found on the surface of many cancer cells that helps them grow and divide. By inhibiting EGFR, Erlotinib can slow or stop the growth of cancer cells. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer.

Erlotinib is particularly effective in NSCLC patients with activating mutations in the EGFR gene, where it can significantly improve progression-free survival and overall response rates. Its targeted mechanism of action distinguishes it from traditional chemotherapy, offering a more personalized approach to cancer treatment. It is taken orally, providing a convenient administration route for long-term therapy.

Uses

• Treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
• Maintenance therapy for advanced NSCLC after initial chemotherapy.
• Treatment of advanced pancreatic cancer in combination with gemcitabine.
• Second-line treatment for advanced NSCLC after failure of at least one prior chemotherapy regimen.

Directions For Use

Take this medication orally, usually once daily, on an empty stomach (at least one hour before or two hours after food). Follow your doctor's instructions precisely.

Benefits

• Targets specific EGFR mutations in cancer cells.
• Improves progression-free survival in eligible NSCLC patients.
• Offers an oral, convenient treatment option.
• Can be effective in patients who have failed other therapies.
• Reduces tumor growth and spread.
• Provides a personalized treatment approach for certain cancers.

Side Effects

• Rash (acne-like)
• Diarrhea
• Nausea and vomiting
• Fatigue
• Anorexia
• Dry skin
• Conjunctivitis
• Stomatitis (mouth sores)
• Hair changes
• Interstitial lung disease (rare but serious)
• Liver function abnormalities
• Gastrointestinal perforation (rare)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during cancer treatment.
• Pregnancy - Erlotinib can cause fetal harm. It is not recommended during pregnancy, and effective contraception should be used during treatment and for at least 2 weeks after the last dose.
• Breastfeeding - It is unknown if Erlotinib is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustment may be necessary for severe liver dysfunction. Liver function should be monitored.
• Kidney - No specific dose adjustment is typically required for renal impairment.
• Lung - Rare but serious interstitial lung disease (ILD) can occur. Patients should be monitored for new or worsening pulmonary symptoms like cough, dyspnea, or fever.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.